Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COMBACTE-NET

Financiado

Combatting Bacterial Resistance in Europe

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international... ver más

28/02/2021

ASTRAZENECA AB

221M€

Presupuesto del proyecto: 221M€

Líder del proyecto

ASTRAZENECA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 32 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2021-02-28 No tenemos la información de la convocatoria

0% 100%

32 Participantes

ASTRAZENECA AB

Lider

FUNDACION PRIVADA INSTITUTO...

N.D. | Participante

SERMAS

N.D. | Participante

CONSORCI INSTITUT D INVESTIG...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DRIVE-AB DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE 11M€ Cerrado

ENZYBIOTX Upgrading business potential of Enzybiotx 75K€ Cerrado

ChronosAntibiotics Exploring the bacterial cell cycle to re sensitize antibioti... 3M€ Cerrado

EUIN2015-62512 PREPARACION DE LA PROPUESTA ERC: ELUCIDANDO LA RESISTENCIA D... 10K€ Cerrado

MuFLOART Microbiological fluorescence observatory for antibiotic resi... 149K€ Cerrado

AGL2016-75536-P EVALUACION DE LOS BACTERIOFAGOS EN LA TRANSFERENCIA DE GENES... 203K€ Cerrado

Duración del proyecto: 97 meses Fecha Inicio: 2013-01-01
Fecha Fin: 2021-02-28

Líder del proyecto

ASTRAZENECA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 221M€

Descripción del proyecto The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need. The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores